Abstract:

[Abstract] Objective   To investigate the role of glucagon peptide-1(GLP-1) in blood pressure variability (BPV) in
diabetic hypertensive patients.Methods   A total of120diabetic hypertensive patients were included in this study. GLP-1 was used for the treatment. The values of body mass index (BMI), fasting blood glucose, glycosylated hemoglobin, creatine and24-hour ambulatory blood pressure (BP) monitoring were detected before and after treatment with GLP-1for six months. The clinical indices were compared before and after treatment.Results   The values of fasting blood glucose (mmol/L:7.12±0.64vs9.19±2.78), glycosylated hemoglobin (%:7.00±0.14vs8.28±1.32) and BMI (kg/m2
:19.30±3.24vs24.5±4.53) were de?creased to the normal level after GLP-1treatment for six months (P<0.05). There were significant decrease in the 24-h sys?tolic BP (mmHg:135.02±16.57vs139.52±15.60), daytime systolic BP (mmHg:132.5±14.6vs136.44±14.24), 24-h systolic BP variability (mmHg:12.20±1.44vs12.73±1.66), daytime systolic BP variability (mmHg:11.11±1.48vs11.74±1.52), and daytime diastolic BP variability (mmHg:7.03±1.42vs7.43±1.45) after GLP-1treatment for six months (P<0.05). Conclu?sion   GLP-1can decrease BPV in diabetic hypertensive patients.

Key words: Glucagon peptide-1, diabetes mellitus, type2, hypertension, blood pressure variability